Skip to main content
Figure 7 | Journal of Neuroinflammation

Figure 7

From: Reduction of β-amyloid pathology by celastrol in a transgenic mouse model of Alzheimer's disease

Figure 7

Chronic effects of celastrol on brain Aβ levels. Five month-old Tg PS1/APPsw mice were implanted subcutaneously with biodegradable placebo pellets and celastrol pellets ensuring a constant release of celastrol at a rate of 2.5 mg/Kg of body weight/day. After 32 days of treatment, brain Aβ levels were analyzed by electrochemoluminescence. A) Histogram representing the level of soluble Aβ 1-38, Aβ 1-40 and Aβ 1-42 quantified in the brain of placebo and celastrol treated Tg PS1/APPsw mice. B) Histogram representing the level of insoluble Aβ 1-38, Aβ 1-40 and Aβ 1-42 quantified in the brain of placebo and celastrol treated Tg PS1/APPsw mice. Multivariate analysis reveals a statistical significant differences between celastrol and placebo treated mice for the levels of brain soluble Aβ 1-38 (P < 0.005), Aβ 1-40 (P < 0.03), Aβ 1-42 (P < 0.007) and brain insoluble Aβ 1-38 (P < 0.004), Aβ 1-40 (P < 0.03), Aβ 1-42 (P < 0.02). (* P < 0.05); ** P < 0.01).

Back to article page